By far the most extensive study of the effect of levamisole in HLA-B27-associated diseases was by Goebel et al.128 They studied 37 men with seronegative HLA-B27-positive spondyloarthritis, including 18 classical cases of AS, 14 cases of RS, and five cases of psoriatic arthritis in a randomised cross-over trial over a period of 12 weeks. There was a significant clinical improvement in the levamisole group compared with placebo, and also some laboratory parameters showed significant improvement. Out of about 50 levamisole-treated cases of RS 15 (30%) showed adverse reactions, mostly mild, including maculopapular rash, nausea and vomiting, and leucopenia. Two patients developed agranulocytosis but recovered spontaneously within a few days. My experience of levamisole so far is limited to giving it to 20 patients with 'drug refractory' RS. Fifteen of them distinctly improved. Out of 15 patients with AS the results were encouraging in eight ( Table) .
It seems that levamisole can benefit severe cases of RS, but extensive studies are still required to establish this. Levamisole seems more effective in treating oligo-and polyarthritis; less effective in improving spondylitis, stomatitis, and urethritis; III. Management Suppl. p. 101 
